The UK market for weight loss treatments has expanded with the private availability of the Wegovy pill, offering an oral alternative to the popular GLP-1 injectable drugs. This development marks a significant step for individuals who meet specific health criteria and are seeking non-injectable options to manage their weight. While the weekly Wegovy injection has been accessible via private prescription and, in limited cases, through the NHS, the introduction of a daily tablet provides a new choice for consumers, though with distinct usage requirements and cost implications.
Access to the Wegovy pill, like its injectable counterpart, is currently limited to private prescription in the UK. Eligibility criteria are stringent, typically requiring a Body Mass Index (BMI) of 30 or above. Individuals with a BMI between 27 and 30 may also qualify if they have at least one weight-related health condition, such as type 2 diabetes or high blood pressure. For those already on the injectable form who have achieved weight loss, there may be some flexibility for continuing on a maintenance dose, subject to prescriber assessment. It is crucial for prospective users to ensure they obtain the medication from legitimate, registered pharmacies that conduct thorough health checks.
In terms of cost, the Wegovy pill is currently priced similarly to the injections, with monthly supplies ranging from approximately £99 for the entry-level dose to around £250 for the highest dose. Some private pharmacies, such as Superdrug, have reportedly offered introductory discounts, reducing the starting dose to £79 for a 30-day supply for new patients. While the long-term hope is that oral weight-loss medications will become more affordable due to lower production costs compared to injections, significant price reductions are not anticipated in the immediate future. This is primarily due to patent protections, with Wegovy's patent for the active ingredient semaglutide jab extending until 2028 and Mounjaro's until 2032.
Choosing between the Wegovy pill and the injection involves weighing lifestyle factors. The pill must be taken daily, first thing in the morning on an empty stomach after an eight-hour fast, with no food or drink for another 30 minutes. In contrast, the injection is administered once weekly, at any time, regardless of food intake, though it requires refrigeration when unopened. Both forms contain the same active ingredient, semaglutide, and clinical trials confirm their effectiveness for weight loss. However, studies indicate the injection is slightly more effective, resulting in an average body weight reduction of 16% from starting weight, compared to 13.6% for the pill.
The introduction of the Wegovy pill could have a modest economic impact on UK households and healthcare spending. For individuals, the ongoing private cost represents a significant monthly outlay, which could affect discretionary spending. Businesses in the pharmaceutical retail sector may see increased demand, though the overall economic impact will be tempered by the private-only access and the relatively high cost. The Bank of England's current focus on inflation and interest rates means that any additional household expenditure, even on health-related items, contributes to the broader economic picture, albeit on a micro level for this specific product. As long as these drugs remain under patent, the financial burden on consumers is likely to persist.